International Stem Cell Corp. ISCO Archives

FridayJun 29, 2012 4:59 pm

Seeking Alpha Article Features International Stem Cell Corp. (ISCO), Touts Stem Cell Technology’s Bright Future

In an article published earlier today featuring key players in the stem cell industry, International Stem Cell Corp. was labeled as being possibly "the most promising" as the company has developed a breakthrough technology that provides pluripotent stem cells without using viable human embryos and without the issues associated with induced pluripotent stem cells or adult stem cells. Based upon unfertilized human eggs, ISCO's technology also allows superior immune-matching capabilities. The idea behind stem cells has in fact been around for a very long time. Ever since the invention of the microscope and the development of cell theory, scientists have…

ThursdayJun 28, 2012 8:42 am

International Stem Cell Corp. (ISCO) Creates Transplantable Human Cornea from Pluripotent Stem Cells

International Stem Cell Corporation’s research and development team has successfully created a functional and transplantable human cornea by developing a new method to derive corneal endothelium-like cells from human pluripotent stem cells. This major milestone represents a significant step towards the creation of complete cornea tissue that can be used for transplantation. The accomplishment also supports prior data showing indications of corneal endothelium generated by ISCO's collaborators at Sankara Nethralaya Eye Hospital, India. Such cells by themselves could promote wound healing and regeneration of the cornea, as well as be used as a standalone medical treatment. ISCO stated that development…

ThursdayJun 21, 2012 1:24 pm

The Critical Value of Parthenogenetic Stem Cells from International Stem Cell Corp. (ISCO)

Parthenogenesis is a term that comes from the Greek word for virgin, parthenos, and genesis, from the Greek word gignesthai, meaning to be born. It’s a good descriptive name for the powerful new stem cell technology developed by International Stem Cell Corporation. Unlike embryonic stem cells, generated from early stage embryos, parthenogenesis utilizes unfertilized human eggs to create what are called parthenogenetic stem cells (hpSC). By using unfertilized human eggs, the cells inherit a duplicate set of human leukocyte antigen (HLA) genes. This significantly reduces the possibility of the derived cells being rejected by an individual’s immune system, making a…

ThursdayJun 14, 2012 8:59 am

International Stem Cell Corp. (ISCO) Announces Discovery of New Protein-Based Stem Cell Technology

Today, International Stem Cell Corp. announced that its wholly-owned subsidiary, Lifeline Cell Technology (LCT), has developed a technology to modify human stem cells by using engineered proteins, called "transducible transcription factors" or "TTFs." TTFs are designed to pass into stem cells and direct the stem cells to change into specific cell types. This technology can be both therapeutically useful and be used as revenue-generating research products. Unlike more traditional cell therapy methods, this new technology does not require the use of viruses or chemicals. Furthermore, the TTF proteins are naturally eliminated by the cells when no longer required, a characteristic…

TuesdayJun 12, 2012 8:54 am

International Stem Cell Corp. (ISCO) Ramps Up Marketing for Lifeline Skin Care

International Stem Cell Corporation, developer of the parthenogenesis process for generating stem cells without the need for fertilized embryos, has announced new sales and marketing initiatives for its stem cell based skin care products produced through subsidiary Lifeline Skin Care. New integrated advertising campaigns will be launched during June and July, in magazines, newspapers, and through direct mail, as well as online. Additional moves are being made through partners and other channels. • Consumer Advertising – The online, newspaper, magazine, and direct mail campaigns will feature Lifeline’s innovative stem cell technology and proof of the brand’s potential for younger looking…

FridayJun 08, 2012 12:31 pm

International Stem Cell Corp. (ISCO) Led by Highly Skilled Leadership

International Stem Cell Corporation, developer of parthenogenesis, a unique process for deriving high quality stem cells without the need for fertilized embryos, is led by a team of executives with international experience, especially valuable in the globally-oriented field of stem cell research and development. • Andrey Semechkin, PhD, Professor, Co-Chairman and CEO, is a specialist in systems analysis, strategic planning, and corporate management. He is a member the Russian Academy of Sciences and has been the Deputy Director of the Institute of System Analysis since 2004. He was awarded the Russian Government Award in Science and Technology in 2006 and…

MondayJun 04, 2012 12:31 pm

International Stem Cell Corp. (ISCO) and Lifeline Skin Care

Underlying the value of stem cells in promoting health and regeneration is their versatility. Stem cells can be programmed to become many different types of cells, providing the potential for tissue regeneration and other remarkable healthcare applications. International Stem Cell Corporation, through the development of parthenogenesis, a unique process for deriving stem cells without the need for fertilized embryos, has opened the door to improved production and the potential treatment of many diseases. In addition to International Stem Cell’s ongoing research into stem cell production and the treatment of disease, the company also has a wholly-owned subsidiary, called Lifeline Skin…

TuesdayMay 29, 2012 11:57 am

International Stem Cell Corp. (ISCO) Targets a Range of Diseases

International Stem Cell has developed a way to derive high quality stem cells without the need for fertilized embryos. Called parthenogenesis, the new process is seen as a source for stem cells that could treat a number of degenerative diseases, including diabetes, liver disease, retinal degeneration, spinal traumas, and other central nervous system injuries. • Age related macular degeneration is one of the leading causes of blindness. Fully one third of all Americans over the age of 50 are considered at risk of developing the disease. Retinal cell transplantation has been shown to benefit patients and may become a key…

WednesdayMay 23, 2012 4:58 pm

International Stem Cell Corp. (ISCO) Offers Stem Cells with Unmatched Advantages

International Stem Cell Corp., based in Oceanside, California, is a stem cell therapeutics company with a powerful new stem cell technology called “parthenogenesis,” which is expected to significantly advance the field of regenerative medicine by addressing the important issue of immune-rejection. Parthenogenetic stem cells are derived from parthenogenetically activated human oocytes, where electrical or chemical stimuli replaces fertilization. Although not derived from fertilized eggs, these activated oocytes can be developed to the blastocyst stage which can give rise to a parthenogenetic stem cell line. Of the several different types of stem cells, parthenogenetic stem cells (hpSCs) offer a unique combination…

WednesdayMay 16, 2012 9:16 am

International Stem Cell Corp. (ISCO) Reports Q1 2012 Financial Results and Business Highlights

Today before the opening bell, International Stem Cell Corporation announced its financial results for the three months ended March 31, 2012. Consolidated net revenues for the period were $1.08 million compared to $1.52 million a year earlier. The year-over-year decrease in revenues is due to fewer sales generated from the Lifeline Skin Care (LSC) direct sales channel, partially offset by higher Lifeline Cell Technology (LCT) sales generated from larger distributors. LSC and LCT accounted for 51% and 49% of total revenue in the three months ended March 31, 2012 compared to 75% and 25%, respectively, in the comparable period a…

Site Search

Company Search

Tag: International Stem Cell Corp. ISCO